The Wockhardt Group, formerly a prominent player in the pharmaceutical industry, is facing financial challenges. With mounting debts and a struggling business, the group's significant assets are now scheduled for auction. This dramatic turn of events has sent shockwaves through the industry, raising eyebrows among analysts. It remains uncertain wh